8-K: Oncolytics Biotech Changes Auditors Amid Restructuring

Oncolytics Biotech Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP due to corporate restructuring.

Summary

• Oncolytics Biotech Inc. announced on July 6, 2026, that its Audit Committee has decided to change its independent registered public accounting firm.
• Ernst & Young LLP (EY) has been disengaged, and Baker Tilly US, LLP (Baker Tilly) has been engaged as the new independent registered public accounting firm for the fiscal year 2026, subject to Baker Tilly's client acceptance procedures.
• This change is attributed to the Company's corporate restructuring.
• EY's reports for the fiscal years ended December 31, 2025, and December 31, 2024, did not contain adverse opinions or disclaimers, but did include an explanatory paragraph regarding the Company's ability to continue as a going concern.
• There were no disagreements with EY on accounting principles, financial statement disclosures, or auditing procedures during the relevant periods.
• Oncolytics Biotech Inc. has not consulted with Baker Tilly regarding any accounting or auditing matters prior to their engagement.
• EY has confirmed agreement with specific statements made by the Company regarding EY in the Form 8-K filing.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the mention of corporate restructuring and the prior auditor's 'going concern' note, which raises questions about the company's financial health despite the lack of auditor disagreements.

Positives

• The change in auditors is a standard procedure during corporate restructuring.
• There were no disagreements with the former auditor (EY) on accounting principles or practices.
• EY's previous reports did not contain adverse opinions or disclaimers, indicating a lack of significant accounting disputes.
• The company has proactively engaged a new auditor for the upcoming fiscal year.

Negatives

• EY's reports for fiscal years 2024 and 2025 contained an explanatory paragraph regarding the Company's ability to continue as a going concern, indicating potential financial instability.
• The need for a corporate restructuring suggests underlying business challenges or strategic shifts.

Risks

• The company's ability to continue as a going concern, as noted in previous auditor reports, remains a potential risk.
• The corporate restructuring itself may introduce operational or financial risks during the transition period.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. The engagement of a new auditor is subject to Baker Tilly's client acceptance procedures.

Management Comments

• The Audit Committee of the Board of Directors of Oncolytics Biotech Inc. unanimously voted to disengage Ernst & Young LLP as the Company's independent registered public accounting firm and to engage Baker Tilly US, LLP as the Company's independent registered public accounting firm for the 2026 fiscal year, subject to completion of Baker Tillys client acceptance procedures, due to the Companys corporate restructuring.

Industry Context

StockSavvy.ai notes that auditor changes, especially when linked to corporate restructuring, are common events in the biotechnology sector as companies evolve, face financial pressures, or undergo strategic realignments. The mention of a 'going concern' by the previous auditor is a critical signal for investors in this high-risk industry.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the auditor change and prior 'going concern' note with caution, potentially impacting investor confidence and stock valuation. The corporate restructuring may also signal strategic shifts that could affect future returns.
• Creditors: The 'going concern' note could raise concerns about the company's ability to meet its financial obligations.
• Employees: Corporate restructuring can lead to uncertainty regarding job security and operational changes.

Next Steps

• Baker Tilly US, LLP to complete client acceptance procedures.
• Baker Tilly US, LLP to serve as the independent registered public accounting firm for the 2026 fiscal year.
• Ernst & Young LLP to provide a letter to the SEC confirming agreement with the statements made by the Company regarding EY.

Key Dates

Recommendation

The filing indicates a change in auditors due to corporate restructuring and notes a prior 'going concern' issue. While there are no direct disagreements with the former auditor, these factors suggest underlying financial or strategic challenges that warrant further investigation before a more definitive recommendation can be made. A 'hold' position allows for monitoring of the restructuring's progress and the new auditor's findings.

Keywords

Oncolytics Biotech, 8-K, Auditor Change, Ernst & Young, Baker Tilly, Corporate Restructuring, Going Concern, SEC Filing, Financial Reporting